{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007293","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.455807+00:00","generated_at":"2026-05-16T20:45:05.071857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aptose reports Q3 net loss $5.1M, cash $1.6M, but TUS+VEN+AZA shows 100% CR/CRh at higher doses","bullets":["Net loss $5.1M (-$2.01/share) for Q3 2025 vs $7.0M (-$11.33/share) in Q3 2024; nine-month net loss $17.7M.","Cash and equivalents $1.6M as of Sep 30, 2025; company states insufficient cash to fund operations, relying on Hanmi advances.","TUS+VEN+AZA triplet: 6/6 (100%) achieved CR/CRh at 80/120 mg TUS doses, exceeding 66% expected from VEN+AZA alone; overall 9/10 (90%) CR/CRh.","Dose escalation to 160 mg TUS underway; updated data to be presented at ASH December 2025.","Shareholders' deficit of $19.5M; company actively pursuing financing and cost reductions."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007293","json":"https://secwatch.observer/filing/0001171843-25-007293.json","markdown":"https://secwatch.observer/filing/0001171843-25-007293.md","text":"https://secwatch.observer/filing/0001171843-25-007293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325007293/0001171843-25-007293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325007293/f8k_111325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:45:05.071857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}